carl zeiss meditec ag - CZMWY

CZMWY

Close Chg Chg %
31.10 0.25 0.79%

Open Market

31.35

+0.25 (0.79%)

Volume: 334.00

Last Updated:

May 1, 2026, 11:33 AM EDT

Company Overview: carl zeiss meditec ag - CZMWY

CZMWY Key Data

Open

$31.52

Day Range

31.25 - 31.52

52 Week Range

26.65 - 75.01

Market Cap

$2.72B

Shares Outstanding

87.54M

Public Float

N/A

Beta

1.53

Rev. Per Employee

N/A

P/E Ratio

17.44

EPS

$1.34

Yield

126.65%

Dividend

$0.39

EX-DIVIDEND DATE

Mar 30, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

4.52K

 

CZMWY Performance

1 Week
 
0.67%
 
1 Month
 
8.51%
 
3 Months
 
-6.38%
 
1 Year
 
-53.82%
 
5 Years
 
N/A
 

CZMWY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 14
Full Ratings ➔

About carl zeiss meditec ag - CZMWY

Carl Zeiss Meditec AG engages in the development, manufacture, and marketing of medical devices. It operates through the Ophthalmic Strategic Business Unit (SBU) and Microsurgery business SBU segments. The Ophthalmic SBU segment includes intraocular lenses, surgical visualization solutions, and medical laser and diagnostic systems. The Microsurgery SBU segment offers surgical microscopes and visualization solutions for neuro, ear, nose, and throat surgery, as well as the activities in the field of intraoperative radiotherapy. The company was founded in 2002 and is headquartered in Jena, Germany.

CZMWY At a Glance

Carl Zeiss Meditec AG
Göschwitzer Strasse 51-52
Jena, Thueringen 07745
Phone 49-3641-220331 Revenue 2.46B
Industry Medical Specialties Net Income 155.90M
Sector Health Technology 2025 Sales Growth 9.814%
Fiscal Year-end 09 / 2026 Employees 5,784
View SEC Filings

CZMWY Valuation

P/E Current 16.62
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 27.815
Price to Sales Ratio 1.763
Price to Book Ratio 1.744
Price to Cash Flow Ratio 18.72
Enterprise Value to EBITDA 11.893
Enterprise Value to Sales 2.046
Total Debt to Enterprise Value 0.142

CZMWY Efficiency

Revenue/Employee 425,208.708
Income Per Employee 26,953.901
Receivables Turnover 3.026
Total Asset Turnover 0.623

CZMWY Liquidity

Current Ratio 2.354
Quick Ratio 1.44
Cash Ratio 0.05

CZMWY Profitability

Gross Margin 52.755
Operating Margin 11.528
Pretax Margin 8.703
Net Margin 6.339
Return on Assets 3.948
Return on Equity 6.543
Return on Total Capital 4.871
Return on Invested Capital 5.127

CZMWY Capital Structure

Total Debt to Total Equity 28.697
Total Debt to Total Capital 22.298
Total Debt to Total Assets 17.557
Long-Term Debt to Equity 26.632
Long-Term Debt to Total Capital 20.694
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Carl Zeiss Meditec Ag - CZMWY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.06B 2.23B 2.24B 2.46B
Sales Growth
+4.58% +8.22% +0.57% +9.81%
Cost of Goods Sold (COGS) incl D&A
838.36M 941.74M 1.06B 1.16B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
75.45M 78.94M 143.92M 139.53M
Depreciation
42.67M 46.79M 56.27M 57.89M
Amortization of Intangibles
32.78M 32.15M 87.65M 81.64M
COGS Growth
+3.24% +12.33% +12.51% +9.66%
Gross Income
1.22B 1.29B 1.18B 1.30B
Gross Income Growth
+5.51% +5.40% -8.18% +9.95%
Gross Profit Margin
+59.26% +57.71% +52.69% +52.76%
2022 2023 2024 2025 5-year trend
SG&A Expense
779.51M 898.36M 929.93M 1.01B
Research & Development
315.09M 372.29M 371.90M 360.22M
Other SG&A
464.43M 526.07M 558.03M 653.72M
SGA Growth
+10.84% +15.25% +3.51% +9.03%
Other Operating Expense
- - - -
-
Unusual Expense
9.30M 11.19M 20.80M 21.30M
EBIT after Unusual Expense
430.59M 375.65M 229.30M 262.22M
Non Operating Income/Expense
15.59M 81.30M 66.96M (18.82M)
Non-Operating Interest Income
14.33M 29.96M 24.28M 7.25M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
9.84M 16.25M 31.89M 29.37M
Interest Expense Growth
-4.00% +65.19% +96.22% -7.92%
Gross Interest Expense
9.84M 16.25M 31.89M 29.37M
Interest Capitalized
- - - -
-
Pretax Income
436.34M 440.69M 264.37M 214.03M
Pretax Income Growth
+7.70% +1.00% -40.01% -19.04%
Pretax Margin
+21.20% +19.79% +11.80% +8.70%
Income Tax
116.34M 128.50M 65.81M 56.91M
Income Tax - Current - Domestic
116.01M 115.28M 88.46M 71.10M
Income Tax - Current - Foreign
- - - 8.26M
-
Income Tax - Deferred - Domestic
855.40K 13.22M (22.65M) (14.19M)
Income Tax - Deferred - Foreign
- - - (8.79M)
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
320.00M 311.25M 195.28M 157.15M
Minority Interest Expense
2.17M 1.72M 1.55M 1.25M
Net Income
317.84M 309.53M 193.73M 155.90M
Net Income Growth
+12.58% -2.62% -37.41% -19.53%
Net Margin Growth
+15.45% +13.90% +8.65% +6.34%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
317.84M 309.53M 193.73M 155.90M
Preferred Dividends
- - - -
-
Net Income Available to Common
317.84M 309.53M 193.73M 155.90M
EPS (Basic)
3.5536 3.4607 2.1804 1.781
EPS (Basic) Growth
+12.58% -2.61% -37.00% -18.32%
Basic Shares Outstanding
89.44M 89.44M 88.85M 87.54M
EPS (Diluted)
3.5536 3.4607 2.1804 1.781
EPS (Diluted) Growth
+12.58% -2.61% -37.00% -18.32%
Diluted Shares Outstanding
89.44M 89.44M 88.85M 87.54M
EBITDA
515.34M 465.78M 394.02M 423.05M
EBITDA Growth
-2.04% -9.62% -15.41% +7.37%
EBITDA Margin
+25.04% +20.92% +17.59% +17.20%

Snapshot

Average Recommendation HOLD Average Target Price 34.021
Number of Ratings 14 Current Quarters Estimate 0.55
FY Report Date 06 / 2026 Current Year's Estimate 1.756
Last Quarter’s Earnings 0.43 Median PE on CY Estimate N/A
Year Ago Earnings 1.893 Next Fiscal Year Estimate 2.208
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 13 13
Mean Estimate 0.55 0.82 1.76 2.21
High Estimates 0.62 0.90 2.00 2.46
Low Estimate 0.51 0.77 1.08 1.82
Coefficient of Variance 10.69 8.45 14.11 8.86

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 2
OVERWEIGHT 1 1 0
HOLD 11 14 15
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Hold Hold Hold

Carl Zeiss Meditec Ag in the News